PDCD1 and neoplasm: Inhibition of this pathway—either by targeting P2Y6 in TAMs or cytidine deaminase (CDA) in tumor cells—restored cytotoxic T-cell infiltration and sensitized tumors to anti-PD-1 therapy [40].